Harvard Heart Letter

Heart Beat: Uncertainty dogs Zetia and Vytorin

The cholesterol-lowering drug ezetimbe, sold as Zetia and in combination with the statin Zocor as Vytorin, has proved no better at reducing plaque than the statin alone, and may be linked to an increased risk of cancer.

To continue reading this article you must be registered.

Get Licensed Content to Harvard Health

If you are interested in licensing content from Harvard Health Publications, please contact us using our online form. Our licensing and business development professionals will help you leverage consumer health content from Harvard Medical School as a clear differentiator in helping achieve your business goals.

Contact Us

Customer Log In